Protocol Title: A Phase 1B Dose-Range Study to Evaluate the Safety, Pharmacokinetics, and Effects of (+)-calaonlide A on surrogate markers in HIV-positive patients with no previous antiretroviral therapy. Protocol ID numbers: FDA 297A.
Reuters Health. Anti-HIV herbal product shows therapeutic potential in phase I trial. November 1, 1999.
Newman RA, Chen W, Madden TL. Pharmaceutical properties of related calanolide compounds with activity against human immunodeficiency virus. J Pharm Sci 1998;87:1077-80.
Buckheit RW, White EL, Fliakas-Boltz V, et al. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother 1999;43:1827-34.
Boyer PL, Currens MH, McMahon JB. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1993;67:2412-20.
Currens MJ, Nariner JM, McMahon JB, Boyd MR. Kinetic analysis of inhibition of human immunodeficiency virus type-a reverse transcriptase by calanolide A. J Pharmacol Exp Ther 1996;279:652-61.
Currens MJ, Gulakowski RJ, Mariner JM, et al. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J Pharmacol Exp Ther 1996;279:645-51.
De Clercq, E. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med.Res Rev. 2000;20(5):323-349.
Itoigawa, M., Ito, C., Tan, H. T., Kuchide, M., Tokuda, H., Nishino, H., and Furukawa, H. Cancer chemopreventive agents, 4-phenylcoumarins from Calophyllum inophyllum. Cancer Lett. 8-10-2001;169(1):15-19.
Sekino, E., Kumamoto, T., Tanaka, T., Ikeda, T., and Ishikawa, T. Concise synthesis of anti-HIV-1 active (+)-inophyllum B and (+)-calanolide A by application of (-)-quinine-catalyzed intramolecular oxo-Michael addition. J Org Chem 4-16-2004;69(8):2760-2767.
Laure, F., Herbette, G., Faure, R., Bianchini, J. P., Raharivelomanana, P., and Fogliani, B. Structures of new secofriedelane and friedelane acids from Calophyllum inophyllum of French Polynesia. Magn Reson.Chem 2005;43(1):65-68.
Yimdjo, M. C., Azebaze, A. G., Nkengfack, A. E., Meyer, A. M., Bodo, B., and Fomum, Z. T. Antimicrobial and cytotoxic agents from Calophyllum inophyllum. Phytochemistry 2004;65(20):2789-2795.
Le Coz, C. J. Allergic contact dermatitis from tamanu oil (Calophyllum inophyllum, Calophyllum tacamahaca). Contact Dermatitis 2004;51(4):216-217.
Oku, H., Ueda, Y., Iinuma, M., and Ishiguro, K. Inhibitory effects of xanthones from guttiferae plants on PAF-induced hypotension in mice. Planta Med 2005;71(1):90-92.
Potti, G. R. and Kurup, P. A. Antibacterial principle of the root bark of Calophyllum inophyllum: isolation and antibacterial activity. Indian J Exp.Biol. 1970;8(1):39-40.
Patil, A. D., Freyer, A. J., Eggleston, D. S., Haltiwanger, R. C., Bean, M. F., Taylor, P. B., Caranfa, M. J., Breen, A. L., Bartus, H. R., Johnson, R. K., and . The inophyllums, novel inhibitors of HIV-1 reverse transcriptase isolated from the Malaysian tree, Calophyllum inophyllum Linn. J Med Chem 12-24-1993;36(26):4131-4138.
Taylor, P. B., Culp, J. S., Debouck, C., Johnson, R. K., Patil, A. D., Woolf, D. J., Brooks, I., and Hertzberg, R. P. Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors. J Biol.Chem 3-4-1994;269(9):6325-6331.
Spino, C., Dodier, M., and Sotheeswaran, S. Anti-HIV coumarins from Calophyllum seed oil. Bioorg.Med Chem Lett. 12-15-1998;8(24):3475-3478.
Pillai, S. N., Desai, M. V., and Shah, H. M. Antihelminthic properties of Punnakkai Cake (Calophyllum inophyllum). Indian J Mycol Plant Path 1974;4(145):150.
Adeyeye, A. Studies on seed oils of Garcinia kola and Calophyllum inophyllum. Journal Of The Science Of Food And Agriculture 1991;57(3):441-442.
Hemavathy, J. and Prabhakar, J. V. Lipid composition of Calophyllum inophyllum kernel. Journal Of The American Oil Chemists' Society 1990;67(12):955-957.